Phase III, multicenter, European, randomized trial comparing the combination Fludarabine-Cyclophosphamide-Rituximab (FCR) with the combination Fludarabine-Cyclophosphamide-Campath (FCCam) in previously untreated adults with B and C Binet stage B-chronic lymphoid leukemia (B-CLL).

Trial Profile

Phase III, multicenter, European, randomized trial comparing the combination Fludarabine-Cyclophosphamide-Rituximab (FCR) with the combination Fludarabine-Cyclophosphamide-Campath (FCCam) in previously untreated adults with B and C Binet stage B-chronic lymphoid leukemia (B-CLL).

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Rituximab (Primary) ; Alemtuzumab; Cyclophosphamide; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Feb 2012 Primary endpoint 'Progression-free-survival' has not been met.
    • 14 Feb 2012 Results published in the Blood.
    • 10 Dec 2011 Minimal residual disease monitoring outcomes at month 9 using a sensitive 6-color flow cytometry technique have been reported at the 53rd Annual Meeting and Expostion of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top